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The interactions between a causative agent and a susceptible host involve a series of
responses most of which are subclinical or asymptomatic but a few of which are manifested by
clinical illness. The factor(s) which tip the balance are poorly understood in both acute and
chronic diseases. It is designated here as the clinical illness promoting factor (CIPF), a third in-
gredient. Among infected persons some leads have been found as to why clinical illness
develops: in tuberculosis genetic susceptibility plays a key role, as shown in twin studies; in
EBV infections age at the time of infection, genetic, and psychosocial factors determine both
the expression and the severity ofillness; in poliomyelitis age, exercise in the incubation period,
and genetic background are related to the development of paralysis. In the relationship be-
tween viruses and cancer, viruses and chronic diseases, or inanimate pathogens like tobacco
and lung cancer, we know very little as to the factors that result in clinical disease among the
many who are presumably susceptible and fully exposed. Epidemiologic study is urged to iden-
tify this CIPF or "third ingredient."
Our concepts of causation have, for the most part, focused on the establishment
of the causal role of a given factor in the production of a disease or clinical syn-
drome by epidemiological and/or experimental means [1]. This proofoften included
reproduction of the disease in a susceptible laboratory animal or susceptible human
host (as per the Henle/Koch postulates), the demonstration that the disease occurs
more commonly in the presence ofthe suspected factor than in its absence (increased
relative risk), or that removal ofthe factor decreases the incidence ofthe disease (at-
tributable risk). These approaches to causative proof have concentrated mainly on
two ingredients: the suspected factor and the human host.
I suggest it is time we focus on clinical illness promotion factors as "a third ingre-
dient." In his short story of that title 0. Henry relates the tale of a poor girl who has
a piece of beefand a young man who has a potato. Together theyjoin with these two
ingredients to make a stew [2]. It is clear, however, that a third ingredient is
necessary to make a good stew. In this instance the essential third ingredient is an
onion. The rest ofthe story concerns the search for someone with this ingredient. In
epidemiological studies we should also be searching for a third ingredient. The ad-
mixture of a "causative agent" fully clothed with all the potential antigens, on-
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All rights of reproduction in any form reserved.cogenic properties, or other putative pathogenetic factors necessary to produce
disease with a fully susceptible host of the proper age, sex, socioeconomic, and
nutritional status is often insufficient to result in clinical disease. A third ingredient,
or even additional ones, may be needed. This is true of causative factors in both
acute and chronic diseases. While the multi-factorial origin of disease has been
recognized by many authors, I wish to focus on the factor(s) that result in clinical
disease among those exposed to all the risk factors. This I will call "the third ingre-
dient," or the clinical illness promotion factor (CIPF).
ACUTE INFECTIOUS DISEASES
A major riddle in infectious diseases is why some individuals develop clinical ill-
ness as a result of infection while others do not. This variation in host response is
true of most viral infections, although a few, such as rabies and measles infections,
almost always result in clinical illness. Some of the clinical illness promotion factors
influencing the host response are listed in Table 1. Age at the time of infection
is one important determinant of the host response, especially to agents such as
poliomyelitis virus, hepatitis A virus, and Epstein-Barr (EB) virus. With these
agents, greater age ofthe host at the time ofinfection correlates with a greater possi-
bility of clinical illness. Variations in the virulence of strains of virus, in the size of
the inoculum, in the portal of entry, and in the status of the host have also been in-
criminated in producing clinical illness among those infected. Marked host varia-
tions exist, however, even when all these factors are held constant. For example,
hepatitis B virus contaminated one lot of yellow fever vaccine given to over 5000
TABLE 1
Third Ingredients
Factors That Might Influence the Occurrence and
Severity of Clinical Disease among Infected Persons
Age at the time of infection
Alcoholism
Anatomic Defects
Antibiotic or anti-viral resistance
Chronic disease: Either pre- or co-existing
Dosage of organism
Double infections (Viral, bacterial, parasitic, fungal)
Drugs: Self- or physician-administered
Genetic make-up, especially effect on the immune system
latrogenic influences: Other therapies, surgery, etc.
Immune status of host at time of infection
Immune response of host to infection (beneficial or detrimental)
Immunodeficiency: Natural, drug-induced, disease-induced
Mechanism of disease production: Lysis, hypersensitivity, immune-complex
Mutation of organism during course of infection
Perception of illness by patient
Physical status at time of infection
Physical exercise during incubation period or at time of onset
Portal of entry of organism
Pregnancy
Psychosocial factors
Stress
Temperature of body at site of entry and viral multiplication
Trauma
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healthy male soldiers of about the same age at Camp Polk. Each received the same
dose in the same arm on the same day [3]. Of those inoculated 1004 (20 percent)
developed clinical jaundice, and the rest did not. The incubation period from injec-
tion to clinical illness varied from 60 to 154 days (mean 96.4 days). What "third in-
gredient" influenced the variability in host response and incubation period among
these soldiers? Unfortunately, we don't know the answer to this, since no studies
were made to analyze this "natural experiment," and, even if they had been, the
laboratory tools were not available at that time to identify susceptibility and im-
munity or to recognize subclinical infections.
A deliberate search for factors influencing EBV infection and disease (clinical in-
fectious mononucleosis-IM) was made among a single class of cadets at the West
Point Military Academy studied over a four-year period [4,5]. Psychosocial factors
were measured on admission, and leadership and academic records were recorded
during school. Among 432 susceptible cadets, 194 (44.9 percent) became infected
over the four years, and 238 (55.1 percent) remained still susceptible four years later
[4]. Among the 194 EBV-infected cadets, 48 developed clinical IM (24.7 percent),
and 146 (75.3 percent) did not. The reasons for this difference were sought in
psychosocial behavior patterns and in academic achievement. A high commitment
to a military career was associated with a 57.1 percent clinical attack rate among
EBV-infected cadets, and low military commitment with only a 10.7 percent rate of
clinical IM. High military commitment influenced infection and disease in opposite
directions, since it was associated with a low infection rate among susceptibles and
high clinical IM rates among the infected. If one had not separately identified the
susceptibles, the infected, and those with disease, this distinction would have been
obscured. Academic performance also influenced the clinical attack rate in the third
and fourth year. Those susceptible cadets whose academic performance was poorer
in the second semester than in the first semester during the year prior to EBV
seroconversion had a 50 percent clinical attack rate, as compared to only a 5.6 per-
cent clinical attack rate in those with relatively good academic performance in the
second semester compared with the first semester. The level of motivation toward a
military career was inversely related to academic performance. Therefore, high
motivation and poor academic performance correlated with high rates ofclinical IM
(43.5 percent). The serious, well-motivated student who failed in his academic ex-
pectations was, thus, especially susceptible to clinical illness after infection had oc-
curred. This same student, however, was less apt to be exposed and infected. These
studies indicate that if susceptibility, infection, and disease categories can be ob-
jectively identified, the clinical illness promotion factor-here, psychosocial fac-
tors-may emerge as a "third ingredient" rather than being obscured or diluted
out by the presence of immune and unexposed individuals. It should be emphasized
that the biological mechanisms by which psychosocial factors influence infection
and disease in West Point cadets are not known, and these findings may not
necessarily apply to other settings.
Genetics also play an important role in the response of the host to infection.
Earlier investigations of twins and families had suggested that genetics played a role
for the occurrence of paralysis in poliomyelitis [6] and in the occurrence of
rheumatic fever following Group A streptococcal infections [7]. However, quan-
titative evaluation of exposure and the presence of prior immunity within family
units were not adequately considered in these studies. More elegant were the twin
and family analyses of Kallmer and Riesner [8] in tuberculosis, in which the cor-
rected rates for manifest tuberculosis on exposure to an index case in the family were
195ALFRED S. EVANS
7.1 percent in marriage partners, 11.9 percent in half siblings, 25.5 percent in
dizygotic co-twins, and 83.3 percent in monozygotic twins. More recently, the im-
portance of genetics in the control of the immune response to EBV infection has
been established by Purtillo and co-workers [9] in the X-linked lymphoproliferative
syndrome. The ability to identify human leucocyte antigens (HLA) and increasing
knowledge of the genetic loci through which they operate may contribute greatly to
our future knowledge of "the third ingredient," provided we can compare persons
who are known to be infected with controls who are matched in all risk factors and
from which group the immune and unexposed can be excluded.
VIRUSES AND CANCER
How can a "third ingredient" be identified in the virus-cancer relationship? The
three leading candidates for producing a human cancer, Epstein-Barr virus (EBV),
herpes simplex type 2 (HSV-2), and hepatitis B virus (HBV) are all ubiquitous
agents. Infection with them is very common in the settings where the cancers are
most common. The presence or absence of antibody may thus be difficult to inter-
pret in relation to causation, since both cases and controls have antibody. In EBV-
related malignancies the antibody titer has been significantly higher in cases than in
healthy controls. This has been shown for over 80 percent of cases of both African
Burkitt lymphoma and nasopharyngeal cancer and for 30-40 percent of Hodgkin's
cases. Initially, it was not known whether these results were due to viral multiplica-
tion in the tumor itself, to the immunosuppressive therapy given for it, or to an
etiological role for the virus. There are several epidemiological approaches to this
dilemma. One is to demonstrate that EBV infection and high EBV antibody titers
(but not titers of other viral antibodies) preceded the disease, and, thus, might be in-
volved in its pathogenesis. This type of prospective serological study has been done
of EBV antibody titers in African Burkitt lymphoma (ABL) [10] and, in a
preliminary way, in Hodgkin's disease [11] and nasopharyngeal carcinoma (NPC)
[12-14]. In the Burkitt lymphoma study 42,000 children were bled, among whom
31 cases of tumor developed over a five-year period. Pre-tumor sera were available
for 14 of these. The EBV VCA-IgG antibody titer was equal or higher than in con-
trols in 10 of the 14 ABL cases in serum samples obtained seven to 54 months before
the tumor was diagnosed [10]. Other herpes and viral antibody titers were not
elevated. There was a 30-fold increased risk of later Burkitt tumor development in
healthy persons with a twofold or greater EBV antibody titer over controls. In
another study, two cases of Hodgkin's disease developed among 26,000 normal per-
sons who had been bled in Washington County, Maryland, and whose sera had been
stored away [11]. EBV antibodies were uniquely and significantly elevated over con-
trols in sera from these two persons obtained 12 and 21 months prior to diagnosis as
compared with four age/sex matched controls for each. In other studies elevated
EBV IgA antibody titers have been shown in three individuals two and one-half to
five years before diagnosis of NPC [12], in one of seven Alaskans who subsequently
developed NPC [13], and in two Chinese who developed NPC10 months later [14].
The presence of elevated antibody titers prior to illness certainly does not establish
that the virus necessarily caused the tumor, but it does suggest that it may have
played a role directly or indirectly in its pathogenesis.
A second epidemiologic approach is to study those persons already possessing
high EBV antibody levels to determine if a "third ingredient" can be identified that
results in the malignancy. In ABL an added factor is clearly needed to account for
the geographic, seasonal, temporal aspects of the tumor. Most evidence suggests
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that holoendemic malaria plays this role. EBV has been termed the "initiator" and
malaria "the promoter" in this tumor. However, holoendemic malaria is, like EBV,
an almost universal infection in early life in this setting. Its occurrence alone would
be unlikely to account for ABL in persons so widely infected with both agents, unless
strong quantitative differences in the intensity ofparasitemia could be shown. Some
other ingredient must be inducing the tumor in those who are doubly infected. The
search for it is the epidemiological challenge now. In areas where NPC flourishes,
EBV infection is also almost universal [15]. Here genetics have been shown to play a
role because the highest incidence of the tumor occurs in Chinese living in, or derived
from, southern China. In addition, there is almost a fivefold increased risk of NPC
among Chinese themselves in the presence of certain HLA configurations (HL-A2,
SIN2) as compared with Chinese without these HLA characteristics. In one study
the combination of high-risk Cantonese Chinese and the presence of the HLA
characteristics resulted in a 30-40-fold higher incidence in this group than in the
population of India [15]. Thus, high EBV-IgA antibody levels and genetic back-
ground certainly set the stage for NPC, but what third ingredient results in the
tumor?
In Hodgkin's disease prior tonsillectomy, socioeconomic and educational levels,
birth order, prior infectious mononucleosis, and elevated EBV antibody titers have
been incriminated as important risk factors [16]. However, these risk factors have
not been compared in persons with or without high EBV antibody titers to determine
if one of them might represent the third ingredient.
Thus, the epidemiological approach to "the third ingredient" in EBV-related
malignancies is to compare persons with the malignancy to those persons who have
all the pertinent risk factors of the case, including high EBV antibody levels, but
who do not have the tumor. Other viral candidates that will require similar investiga-
tions are HSV-2 in relation to cervical and vulvar cancer, HBV in relation to
hepatocellular cancer, CMV in relation to Kaposi's sarcoma and prostatic cancer,
and retroviruses in relation to leukemia.
VIRUSES AND CHRONIC DISEASE
The role ofviruses in the pathogenesis ofcertain chronic diseases is being increas-
ingly recognized. These involve chronic diseases of the central nervous system
(Kuru, Creutzfeld-Jakob disease, subacute sclerosing panencephalitis, progressive
multi-focal leukoencephalopathy, multiple sclerosis and allied neurological dis-
eases), of the connective tissues and arteries (systemic lupus erythematosus, sar-
coidosis, peri-arteritis nodosa, rheumatoid arthritis), of the kidney (immune com-
plex nephritis), and of the pancreas (Coxsackie and juvenile diabetes). These ex-
citing advances must be evaluated epidemiologically with methods that recognize
susceptibility, infection, and other risk factors in selecting controls. It must be
stressed that (1) no one of these putative causes is likely to cause all cases of the
disease, (2) other factors ("a third ingredient") are needed in addition to a susceptible
host and the putative agent, (3) both the causative agent and the co-factors may be
different in different settings without diminishing their important role in causation
in a particular setting, and (4) a given agent may operate either directly or indirectly
in causation and at different points in the pathogenesis.
DISCUSSION
Advances in molecular virology have yielded very sophisticated techniques to
identify the virus, its genome, or its footprints in tissues and to identify particular
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genome segments that control particular antigenic activities. Second, advances in
producing antibody components of high sensitivity and high specificity, particularly
the use of monoclonal antibodies, have created a new set of tools to examine the
humoral immune response. Third, developments in the study of cell-mediated im-
munity and its genetic control have permitted a better understanding ofthe immuno-
regulation of viral infections. We have learned how this system can both cause and
prevent clinical disease. These new virological, immunological, and genetic advances
are yielding new insights into disease causation and pathogenesis, and they provide
new techniques to the epidemiologist. Causation is increasingly recognized as a
multi-factorial and complex phenomenon with different sets of risk factors operat-
ing in different settings. Many ofthe causes of disease are so ubiquitous that almost
everyone has been exposed to them. This is also true of (direct or indirect) exposures
to certain agents, such as tobacco smoke, which are associated with chronic
diseases. What then makes disease develop in some who have been exposed, but not
in others? It is the search for a clinical illness promotion factor, "a third ingredient,"
that I urge epidemiologists to pursue. It may be external or internal to the host, it
may vary from disease to disease, and it may vary within a single disease in various
epidemiologic settings. To discover it, one must study a disease intensively within a
single ecological setting and compare persons with the disease with exposed and "in-
fected" controls who have all the same risk markers as the cases. In this effort the
epidemiologist should join hands with the virologist, the clinician, the statistician,
the immunologist, the biochemist, and the social scientist. If we can identify and
modify the clinical illness promotion factor(s), then our efforts at control and
prevention can be directed only at those few persons who develop the disease rather
than at the total group who are exposed as is our current practice.
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